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The standard de Gramont (dG) regimen of fortnightly leucovorin, bolus ﬂuorouracil and 22-h infusion of ﬂuorouracil, d1+2,
and the same regimen plus oxaliplatin, are effective but also cumbersome. We therefore present simpliﬁed ‘Modiﬁed de
Gramont’ (MdG) regimens. Forty-six advanced gastrointestinal cancer patients entered a dose-exploring study of MdG,
including an expanded cohort of colorectal cancer patients at optimum dose. Treatment (fortnightly) comprised: 2-h i.v.i.
leucovorin (350 mg d,l-LV or 175 mg l-LV, not adjusted for patient surface area); bolus ﬂuorouracil (400 mg m
72), then
ambulatory 46-h ﬂuorouracil infusion (2000–3600 mg m
72, cohort escalation). Subsequently, 62 colorectal patients (25
unpretreated; 37 ﬂuorouracil-resistant) received MdG plus oxaliplatin (OxMdG) 85 mg m
72. Fluorouracil pharmacokinetics
during MdG were compared with dG. The optimum ﬂuorouracil doses for MdG alone were determined as 400 mg m
72
bolus + 2800 mg m
72 46-h infusion. A lower dose of 400 mg m
72 bolus + 2400 mg m
72 infusion which, like dG produces
minimal toxicity, was chosen for the OxMdG combination. Fluorouracil exposure (AUC0–48 h) at this lower dose is equivalent
to dG. With OxMdG, grade 3–4 toxicity was rare (neutropenia 2.8% cycles; vomiting or diarrhoea 51% cycles), but despite
this there were two infection-associated deaths. Oxaliplatin was omitted for cumulative neurotoxicity in 17 out of 62 patients.
Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%. 1st-line
OxMdG (24 assessable): CR/PR=72%; NC=20%; PD=8%; 2nd line OxMdG (34 assessable): PR=12%; NC=38%; PD=50%.
MdG and OxMdG are convenient and well-tolerated. OxMdG was particularly active as 1st-line treatment of advanced
colorectal cancer. Both regimens are being further evaluated in the current UK MRC phase III trial.
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The de Gramont regimen (dG), also known as ‘LV5FU2’, is one of
several standard methods for administration of 5-ﬂuorouracil (FU)
and leucovorin (LV). It involves a 2-h infusion of LV
(200 mg m
72), bolus injection of FU (400 mg m
72), then 22-h
infusion of FU (600 mg m
72), with the same sequence repeated
on the second day, repeated fortnightly (de Gramont et al,
1988). It was compared with the Mayo Clinic 5-day bolus FU/LV
regimen in a 448-patient randomised trial, and showed a better
response rate (32.6% vs 14.4%; P=0.0004), and median progres-
sion-free survival (27.6 vs 22 weeks; P50.0012) with signiﬁcantly
reduced rates of diarrhoea, mucositis and neutropenia; however,
overall survival was not signiﬁcantly improved (de Gramont et
al, 1997). Following this trial dG was adopted as a standard therapy
option by many oncologists, especially in France and the UK.
Its low toxicity proﬁle makes dG a good basis for combination
chemotherapy. Pivotal trials of the design ‘dG+new agent’ have
been performed in ﬁrst-line therapy of metastatic colorectal cancer
using oxaliplatin (de Gramont et al, 2000) or irinotecan (Douillard
et al, 2000), in each case producing a high response rate and good
safety proﬁle. Similar trials are now ongoing in the adjuvant
setting.
Although dG can be administered on an ambulatory, out-patient
basis, many units ﬁnd it more convenient to admit patients. This,
together with the high dose of LV, and a labour-intensive adminis-
tration schedule, place high demands on healthcare resources (Ross
et al, 1998). Furthermore, repeated hospital visits or admissions
during dG may detract from the beneﬁts of its low toxicity proﬁle.
Along with others (see Discussion), we reasoned that it would be
possible to modify the dG regimen, reducing its costs and making
it universally applicable as an outpatient regimen, whilst exploring
higher FU dose-intensity which might further improve its efﬁcacy.
The ‘Modiﬁed de Gramont’ (MdG) regimens incorporate two main
changes:
(1) LV at a ﬂat dose (350 mg d,l- or 175 mg l-LV, not adjusted for
patient surface area), and on day 1 only. There is no evidence for
a dose-response effect with LV (Ychou et al, 1998), so surface-
area dosing is unjustiﬁed. Prolonged (424 h) high levels of
plasma reduced folate metabolites are obtained after LV infusion
at this dose.
(2) FU is given as a single 400 mg m
72 bolus, then high dose-rate
46-h infusion. This avoids the need for day 2 ward attendance,
reduces nurse and pharmacist time and makes the schedule
more suitable for the out-patient setting.
First, a cohort dose-escalation study was performed to determine
the optimum FU 46-h infusion dose. The aim was to ﬁnd (a)
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combination chemotherapy regimens, and (b) the FU dose most
suitable for further study when MdG is used alone. An expanded
cohort of patients with unpretreated metastatic colorectal cancer
was studied at this latter dose to conﬁrm the activity of the new
MdG regimen. The lower dose was then combined with oxaliplatin
(‘OxMdG’) and studied in patients with FU-resistant or unpre-
treated metastatic colorectal cancer.
FU pharmacokinetics are non-linear, so the higher dose-intensi-
ties of FU commonly achieved with infusional treatment are no
guarantee of increased tumour exposure to the drug. We therefore
performed a pharmacokinetic study to assess FU exposure (area
under the plasma concentration-time curve, AUC) during the
new MdG regimens compared with dG.
PATIENTS AND METHODS
Patients
The studies involved a total of 108 patients (see Table 1). Appro-
priate Institutional and Local Ethics approval was obtained, and all
patients gave written informed consent.
MdG (46 patients) To establish the optimum 46-h FU infusion
dose,anescalation studywasperformedin32patientswithmetastatic
adenocarcinoma of any gastrointestinal primary origin. Eligibility
criteria were WHO performance status 0–2; bilirubin 550 mmol
l
71; ALP and transaminases 536upper limit of normal; WBC
43610
9 l
71; neutrophils 41.5610
9 l
71 and platelets 41006
10
9 l
71.Womenofchildbearingpotentialwererequiredtousecontra-
ception. Previous chemotherapy for metastatic disease was permitted.
Following this, MdG at the 400 mg m
72 bolus + 2800 mg m
72 46-
hinfusiondoselevelwasadoptedinourinstitutionasastandardther-
apy option for patients with metastatic colorectal cancer fulﬁlling the
same eligibility criteria. Toxicity and response data were collected for
afurther14patients,givingatotalof22patientswithmetastaticcolor-
ectalcancer treated atthat dose level foranalysis.
OxMdG (62 patients) Initially, 22 patients with FU-resistant
colorectal cancer were treated with OxMdG in a named-patient
compassionate-use programme. Patients had to have inoperable,
histologically conﬁrmed colorectal adenocarcinoma with progres-
sion during or soon after prior chemotherapy . The same general
ﬁtness and organ function criteria were used as for MdG, with
the addition of GFR 460 ml min
71. From May 1999, the use of
OxMdG in our institution was expanded to a formal phase II trial
including a further ﬁfteen 2nd-line patients (bringing the total to
37) and 25 patients with unpretreated metastatic colorectal cancer.
The same eligibility criteria applied.
Treatment
Single-lumen venous access was established using a subcutaneous
port or Hickman line. Prophylactic warfarin was given, 10 mg on
the day of line insertion then 1 mg daily.
MdG comprised: ﬁxed dose d,l-LV 350 mg (or l-LV, 175 mg) as
a 2-h i.v. infusion; then FU i.v. bolus over 5 min; then 46-h FU
infusion (see Figure 1). Treatment was repeated every 14 days.
MdG was given without routine prophylactic anti-emetics or
anti-diarrhoeals, but patients were supplied with standard doses
of oral metoclopramide and loperamide with written instructions
on their use. The 46-h FU infusion was delivered using a disposa-
ble elastomeric pump (Baxter LV5
1). After the infusion, the line
was ﬂushed by the patient’s community nurse. Hickman lines were
ﬂushed weekly between treatments. For patients without central
venous access, the infusion was given via a peripheral cannula, in
hospital, until access has been established.
OxMdG was preceded by i.v. dexamethasone 8 mg and granise-
tron 1 mg, and followed by oral dexamethasone (4 mg t.d.s. on day
2; b.d. on day 3 and o.d. on day 4). Oxaliplatin 85 mg m
72 was
given concurrently with LV, via a Y-connector, during the ﬁrst
2 h. Each drug was diluted in 250 ml 5% dextrose, and care was
taken to avoid mixing oxaliplatin with saline. Thereafter, OxMdG
was administered in the same way as MdG.
Chemotherapy starting-dose and adjustments
LV was not adjusted for toxicity. The starting-dose for the 5-min
bolus FU was 400 mg m
72 in all patients, both for MdG and
OxMdG. The dose of 46-h FU infusion was studied by dose escala-
tion in the ﬁrst 32 patients receiving MdG. Five dose-levels were
investigated, 2000–3600 mg m
72 (Table 2). Patients were evalu-
ated for toxicity after each cycle (NCI Common Toxicity Criteria
v2.0). After cycle 4, intra-patient dose-escalation to the next level
was permitted providing there had been no acute toxicity greater
than CTC grade 2, or persistent grade 2 toxicity. The aim was to
establish the dose at which treatment could continue indeﬁnitely,
therefore persistent symptomatic grade 2 toxicity was taken as an
indication for dose de-escalation.
After completion of the dose-escalation study, the 46 h FU infu-
sion dose was set at 2800 mg m
72 for patients receiving MdG alone,
and 2400 mg m
72 for patients receiving OxMdG. These doses were
not escalated thereafter. As before, toxicity was scored by the
research nurse at the start of each cycle of chemotherapy. For day
1 WBC, ANC or platelet count of grade 52, or for non-haematolo-
gical toxicity of grade 52 despite symptomatic measures, treatment
was delayed 1 week. If a 2-week delay was required, or two separate
delays of 1 week, subsequent chemotherapy doses (FU bolus; FU
infusion; oxaliplatin, but not LV) were reduced by 20%.
Neurosensory toxicity was scored carefully in patients receiving
OxMdG. Oxaliplatin was not adjusted for temporary cold-induced
dysaethesia, but was omitted from the regimen for peripheral sensory
neuropathy producing pain, numbness or loss of function (NCI CTC
grade 3), if it persisted between chemotherapy cycles. Oxaliplatin was
re-introduced if all symptoms of neuropathy resolved.
Treatment duration was not ﬁxed. Chemotherapy was discontin-
ued at disease progression, but treatment breaks were discussed
with patients whose disease remained controlled after 12 cycles,
resuming the same regimen at a later date.
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Table 1 Patient characteristics
OxMdG OxMdG
MdG 2nd-line 1st-line
Number 46
a 37
b 25
Sex (M:F) 30:16 22:15 19:6
Age: median (range) 68 (43–78) 60 (37–77) 62 (14–77)
Performance status:
01 5 2 0 1 0
11 8 1 1 1 1
21 3 6 4
Primary site:
Colon 19 29 18
Rectum 8 8 7
Other GI 19 – –
Previous chemotherapy:
Adjuvant FU/FA 3 8 6
Pall. bolus FU/FA 4 –
Pall. infusional 5FU 7 28 –
Irinotecan/raltitrexed 4 –
a32 patients in dose-escalation study plus expanded cohort of 14 colorectal cancer
patients at optimum dose level.
b22 patients in compassionate use programme plus
15 in phase II trial.
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Blood tests and clinical evaluation were performed twice-weekly,
tumour marker assays 4-weekly and imaging (CT scanning+other
tests) 12-weekly. Initially, response to chemotherapy was scored
using WHO criteria, but after seeing unexpectedly high activity
in the OxMdG ﬁrst-line therapy cohort, all case notes and scans
in this group were externally reviewed and scored using RECIST
criteria (Therasse et al, 2000) by an independent oncologist and
radiologist.
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MdG (at 400+2400 mg m–2)
AUC0-48 hr = 260 µmol l h
–1
dG, d1 (400+600 mg m–2)
plus:
dG, d2 (extrapolated from d1)
AUC0-48 h = 252 µmol l h–1
Time (h)
FU infusion 600 mg m–2 22 h
FU infusion 2800 mg m
–2 46 h
FU infusion 2400 mg m
–2 46 h
FU bolus
400 mg m–2
Figure 1 dG, MdG and OxMdG. Plasma FU levels are shown for nine patients receiving dG (day 2 data extrapolated from day 1) and in 10 receiving
MdG, at the lower dose of 400 mg m
72 bolus+2400 mg m
72 46 h infusion as used in the OxMdG schedule.
Table 2 Dose-escalation of 46 h FU infusion in the MdG regimen
FU dose
a % Patients
(mg m
72) Started at +Escalated from =Total patients Assessable De-escalated tolerating
over 46 h that level lower level treated for tolerability
b for toxicity this dose
c
2000 8 – 8 6 0 100
2400 10 4 14 11 1 91
2800 24
d 93 3 2 8 5 8 2
3200 4 10 14 14 4 71
3600 0 5 5 4 2 50
aAt all levels patients also received FU 400 mg mg
72 bolus (see Figure 1).
bExcludes patients stopped for disease progression within 3
cycles.
cProportion of assessable patients tolerating 53 cycles.
dIncludes 10 patients in dose-escalation +14 in expanded cohort study.
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Ten patients receiving OxMdG also participated in a study of FU
pharmacokinetics, in which samples were taken during one cycle
of OxMdG and one paired cycle of MdG alone (at the
2400 mg m
72 46-h FU infusion dose). Blood was taken at 10
intervals out to 4 h, and at 24 and 46 h. Samples were cold-spun
and the plasma frozen immediately after collection. Plasma 5-FU
was determined by HPLC analysis (Seymour et al, 1994). The
trapezoidal method was used to calculate FU AUC0–48 h. This
study is reported elsewhere and shows that oxaliplatin does not
signiﬁcantly affect the plasma pharmacokinetics of FU (Joel et al,
2000).
For the current study, data for these 10 patients during MdG are
compared with historical control data from nine patients
previously studied using the same sampling and analytical techni-
ques, in the same laboratory, during treatment with dG. Patients
receiving dG underwent pharmacokinetic sampling during the ﬁrst
24-h period, and these data have been extrapolated to estimate the
FU AUC0–48 h. This assumes approximately equal FU pharmacoki-
netics on days 1 and 2 of the standard dG regimen.
RESULTS
Dose escalation and tolerability of MdG
Data for all 46 patients receiving MdG is summarised in Table 2.
In general, MdG is a well-tolerated and practicable regimen. The
dose-limiting side-effects in the short-term are gastrointestinal
(diarrhoea, mucositis; nausea) and, after longer treatment, derma-
tological (hand/foot dermatitis). There were no episodes of grade
53 haematological toxicity, even at the higher FU doses.
At lower dose levels, toxicity was conﬁned to grade 2 nausea,
diarrhoea, stomatitis or lethargy. One patient was de-escalated
from 2400 to 2000 mg m
72 for grade 4 diarrhoea, but with this
exception 2400 mg m
72 produced minimal toxicity, of a degree
similar to the standard dG regimen.
At 2800 mg m
72, 5 out of 22 assessable patients eventually
required de-escalation, in one case after grade 3 nausea but in all
other cases for persistent grade 2 toxicity (nausea; diarrhoea;
stomatitis; dermatitis). This degree of toxicity is higher than is seen
with the standard dG regimen, but still less than conventional
MTD, and this dose level was selected as the optimum starting
dose for future use of MdG alone. Table 3 shows the maximum
toxicity per patient for the 33 patients who received MdG at this
dose level in either the dose-escalation study or the extended
cohort.
Some patients are able to tolerate higher FU doses. At
3200 mg m
72, 71% patients were able to tolerate three or more
cycles without dose reduction. However, grade 2 toxicities were
frequent and led to dose reductions in 50% of patients after six
cycles, so this dose was not selected for further study. No patients
were entered at 3600 mg m
72 but of the ﬁve patients escalated to
this level only two tolerated it for 4three cycles. There were no
treatment-related deaths at any level.
Tolerability of OxMdG
The 62 OxMdG patients received a total of 778 treatment cycles.
Serious adverse event (SAE) and maximum overall toxicity data
are presented for all cycles in all patients (Table 3). Toxicity-per-
cycle data is given only for the ﬁrst six cycles, in patients on the
formal phase II trial, to avoid bias from dose reductions and differ-
ing data collection methods (Table 4).
The toxicity proﬁle was similar in ﬁrst-line and second-line
patients. Main toxicities were sensory neuropathy, lethargy, diar-
rhoea, nausea and neutropenia. However these rarely exceeded
grade 2 (Table 4). In three patients oxaliplatin was omitted from
the regimen after recurrent myelosuppression (neutropenia and/
or thrombocytopenia) despite appropriate dose reductions. Mild
sensory neuropathy was very common (55% of cycles). Among
the 25 ﬁrst-line patients in the formal phase II trial, nine required
the omission of oxaliplatin for neurotoxicity at some point prior to
treatment failure (median, 12 cycles). In FU-resistant patients,
since disease progression on treatment occurred earlier, fewer (5
out of 37) required omission of oxaliplatin for cumulative toxicity.
Despite the generally favourable toxicity proﬁle, two deaths were
related to treatment (3.2% patients). One patient, after eight
uneventful previous cycles, became progressively unwell over 48 h
without seeking help, then was admitted urgently to the nearest
hospital with neutropenia and respiratory failure, and died within
a few hours. A second patient did not have neutropenia but
succumbed with overwhelming methicillin-resistant Staphylococcus
aureus (MRSA) septicaemia related to the central venous catheter.
Anti-tumour efﬁcacy
The MdG dose-escalation study was not designed to measure efﬁ-
cacy, but eight patients in the 2800 mg m
72 infusion cohort had
unpretreated assessable advanced colorectal cancer. A further 14
colorectal patients were then entered at that level (without escala-
tion) to give a total of 22 patients for a preliminary efﬁcacy
analysis (Table 5). Among these 22 patients, WHO PR was seen
in eight (36%), with MR or SD for 412 weeks in a further seven
(32%). Median failure-free survival (FFS) was 9.3 months. Follow-
ing MdG, 15 of the 22 patients went on to receive second (+third)
line chemotherapy and one responder underwent curative liver
resection. Median overall survival (OS) from starting MdG is
16.8 months.
Tumour response was a formal endpoint of the OxMdG studies
(Table 5). Thirty-four of the 37 second-line patients were assessable
for response. Four patients achieved a conﬁrmed partial response
(12%), one patient an unconﬁrmed partial response (3%) and
twelve (35%) had stable disease for at least 12 weeks. Median
FFS was 4.8 months and median OS 10.7 months from the time
of starting OxMdG.
For the 1st-line OxMdG cohort, all case-notes and scans were
reviewed and scored for response using RECIST criteria, by an
independent oncologist and radiologist appointed by ICRF. One
patient, with disease seen only laparoscopically, was not assessable.
One patient (4%) achieved a complete response; conﬁrmed partial
responses were seen in 17 (68%); unconﬁrmed (by a second scan)
partial responses were seen in a further two patients (8%). In three
patients (12%) disease remained stable for at least 12 weeks. Two
patients progressed, in both cases after two cycles. The overall
response rate (CR + conﬁrmed PR) was 72%. Median failure-free
survival is 10.6 months (range 0.9–24.7) and median overall survi-
val is 16.7 months (range 2.0–26.7+).
Three patients with initially inoperable metastases underwent
liver surgery after responding to OxMdG. Two have since relapsed,
and one responded to re-challenge with the same regimen. One
patient with mediastinal disease underwent consolidation mediast-
inal radiotherapy and remains disease-free 1 year later.
Pharmacokinetics
Figure 1 and Table 6 show FU plasma proﬁles during the standard
dG regimen, or MdG (at the lower, 2400 mg m
72 FU infusion
dose level as used in OxMdG). The total area under the FU
concentration-time curve during the regimen (AUC0–48 h) is simi-
lar for the two regimens (Table 6). This is consistent with the
clinical ﬁnding, during the dose-escalation study, that despite its
higher FU-dose intensity, MdG at this dose has the same minimal
toxicity as standard dG.
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Fluoropyrimidines remain our best ‘single agent’ for colorectal
cancer, and the basis of combination therapy. The optimum ﬂuor-
opyrimidine therapy may continue to be debated, but de
Gramont’s LV5FU2 regimen (dG) is a strong contender, with a
good track record of efﬁcacy and low toxicity in large phase III
randomised trials (de Gramont et al, 1997; Douillard et al, 2000;
Maughan et al, 2002).
New cytotoxic drugs for colorectal cancer have brought the
welcome need to develop safe, effective combination regimens. In
Europe, dG has been combined with oxaliplatin and with irinote-
can, in each case leading to successful phase III trials in advanced
disease. In the ﬁrst trial, 210 patients received oxaliplatin+dG,
grade 53 toxicities were frequent but manageable and one toxic
death (51%) was reported (de Gramont et al, 2000). In the
second, 145 patients received irinotecan+dG, again with signiﬁcant
but manageable grade 53 toxicity, and with one (51%) toxic
death (Douillard et al, 2000). Both regimens are now being assessed
as adjuvant therapy, and whilst full data are awaited, interim toxi-
city reports are reassuring (Rothenberg et al, 2001). But these
regimens are cumbersome for patients and, in this common
disease, place formidable ﬁnancial and human demands on health-
care resources.
Meanwhile, other groups based their combinations on bolus FU/
LV regimens. A phase III trial in advanced disease compared bolus
irinotecan, FU and LV, given weekly for 4 weeks out of 6 (IFL),
against single-agent irinotecan or a FU/LV control: the combina-
tion treatment gave superior response rate and survival, with
broadly similar rates of toxicity (Saltz et al, 2000). On this basis,
IFL became standard care for metastatic colorectal cancer in USA
and entered adjuvant trials, whilst other bolus FU-based combina-
tions were evaluated in advanced disease. However, the toxicity of
these combinations soon became cause for concern. Two novel
schedules, involving irinotecan or oxaliplatin on day 1 with bolus
FU/LV on days 2–5, were withdrawn from the NCCTG N9741
after excessive gastrointestinal and haematological toxicity, with a
total of 10 toxic deaths among the ﬁrst 108 patients treated
(Morton et al, 2001). Subsequently, excess mortality during treat-
ment with the IFL regimen in both N9741 and the CALGB
C89803 adjuvant trial led to interruption of both these trials
(Rothenberg et al, 2001; Sargent et al, 2001), although after a
further review of all available toxicity data the US Oncology Drugs
Advisory Committee decided not to remove the IFL regimen from
the irinotecan product label (http://www.fda.gov/ohrms/dockets/ac/
01/ transcripts/3815t2.rtf).
This leaves a clear need to develop regimens offering the good
efﬁcacy and safety proﬁle of the dG-based combinations, but
more convenient for patients and less demanding of healthcare
resources. One approach is to explore the use of oral FU; the
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Table 3 Maximum toxicity per patient
Maximum grade
MdG (2800 mg m
72) n=33 OxMdG n=62
experienced (%) Gr 0-1 Gr 2 Gr 3 Gr 4 Gr 0-1 Gr 2 Gr 3 Gr 4
Nausea or vomiting 74 13 13 0 75 16 7 2
Mucositis 97 3 0 0 84 10 3 3
Diarrhoea 94 7 0 0 70 18 8 2
Neuropathy (NA) (NA) (NA) (NA) 70 26 3 0
Skin (HFS) 90 3 7 0 100 0 0 0
Lethargy 74 13 13 – 52 31 15 0
Infection 84 10 7 0 59 21 15 5
a
WBC or neutr 97 0 3 0 44 25 26 5
Platelets 100 0 0 0 97 3 0 0
aIncludes two patients with grade 5 (fatal) infection.
Table 4 Toxicity per cycle of OxMdG, cycles 1–6
1st-line (n=145 cycles) 2nd-line (n=137 cycles)
All grades Grades 3–4 All grades Grades 3–4
(%) (%) (%) (%)
Nausea 30 (21) 0 32 (23) 0
Vomiting 11 (8) 2 (1%) 13 (10) 0
Anorexia 16 (8) 0 9 (7) 0
Mucositis 46 (32) 1 (1%) 20 (15) 0
Diarrhoea 29 (20) 1 (1%) 41 (30) 0
Neuropathy 80 (55) 0 76 (55) 0
Skin (HFS) 11 (5) 0 12 (9) 0
Lethargy 62 (43) 3 (2%) 62 (45) 2 (1%)
Infection 2 (1) 2 (1%) 6 (4) 2 (1%)
Neutr. (excl gr 1) 15 (11) 6 (4%) 10 (7) 2 (1%)
Platelets (excl gr 1) 10 (7) 0 10 (7) 0
Data for the 25 1st-line and 15 2nd-line patients treated in the formal phase II study.
Data are presented for cycles 1–6 only, to avoid the inﬂuence of later dose
adjustments.
Table 5 Efﬁcacy of MdG and OxMdG in colorectal cancer patients
MdG
a OxMdG OxMdG
1st-line 2nd-line 1st-line
Total colorectal patients 22 37 25
Assessable for response 22 34 24
Response rate
b CR+PR (%) 36 12 72
Median FFS (months) 9.3 4.8 10.6
Median OS (months) 16.8 10.7 16.7
aMdG at FU 400 mg m
2 bolus plus 2800 mg m
72 46-h infusion dose level.
bResponse assessment: WHO criteria in-house for MdG and FU-resistant OxMdG,
RECIST criteria external independent panel for OxMdG unpretreated patients.
Table 6 Pharmacokinetic comparison of MdG and dG regimens
FU dG (n=9) MdG
a (n=10)
Total FU dose (mg m
72), 0–48 h 2000 2800
AUC0–2h (mmol l
71 h) 82+29 102+14
AUC0–24 h (mmol l
71 h) 126+60 181+31
AUC0–48 h (mmol l
71 h) 252
b 260+43
[FU]SS at 24 h (mmol l
71) 1.4+0.6 3.6+0.6
aMdG at lower dose of 400 mg m
72 bolus+2400 mg m
72 infusion as used in
OxMdG.
bExtrapolated assuming equal FU pk on days 1 and 2 of regimen – see
Figure 1.
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schedules. MdG preserves the main elements of dG: dose-intensive
exposure to FU with LV for 48 h every 2 weeks, with minimal
haematological gastrointestinal toxicity. MdG has not been
compared with dG in a randomised trial; to demonstrate equiva-
lence with reasonable conﬁdence would require at least 1000
patients. However, two factors lend conﬁdence to it: ﬁrstly, its
activity during this pilot study was at least as good as expected
with dG; secondly, the pharmacokinetic analysis shows equiva-
lence in FU exposure (AUC0–48 h) for dG and the lower MdG
dose used in the OxMdG schedule.
Similar but more dose-intensive MdG-like schedules have been
developed by the French oncology group, GERCOR. Their simpliﬁed
bimonthly regimen of FU and LV is similar to MdG but has approxi-
mately double the dose of l-LV (200 mg m
72, instead of 175 mg
unadjusted for surface area), and includes individual titration of
the FU dose up to 3600 mg m
72, which may potentially optimise
5-FU exposure, although the criteria for dose titration are not deﬁned
(Tournigand et al, 1998). In addition to these differences, the equiva-
lent oxaliplatin combination, ‘FOLFOX6’, differs from OxMdG in
using a higher dose of oxaliplatin (100 mg m
72 instead of
85 mg m
72) (Maindrault-Goebel et al, 1999). An even higher
dose-intensity regimen, FOLFOX7, uses oxaliplatin at 130 mg m
72
fortnightly (Maindrault-Goebel et al, 2001).
It is not yet known whether these dose-intensive schedules,
which may be used for only short treatment durations because of
cumulative oxaliplatin neurotoxicity and carry a higher risk of
myelotoxicity, have any advantage over the less dose-intensive
OxMdG. In a preliminary report of a randomised trial examining
the sequencing of oxaliplatin and irinotecan combinations,
FOLFOX6 produced a response rate of 56% with median TTF of
8.9 months among 109 unpretreated patients (Tournigand et al,
2001), which does not suggest superior efﬁcacy to OxMdG (see
Table 5). Conversely, a comparison of response rates and survival
in sequential second-line phase II studies from GERCOR has been
reported as suggestive of an oxaliplatin dose-intensity effect (Main-
drault-Goebel et al, 2000), and OxMdG appeared to perform
relatively less well in our second-line cohort. Perhaps this serves
to underline the unreliability of comparisons between different
phase II studies; a true dose-intensity beneﬁt will only be demon-
strated with a prospective randomised trial.
Our group has also piloted an irinotecan+MdG combination,
‘IrMdG’, which includes irinotecan 180 mg m
72, with encouraging
results (Ledermann et al, 2001). As with OxMdG, IrMdG is less
dose-intensive of l-LV and FU than the equivalent GERCOR
combination, FOLFIRI (Andre et al, 1999).
Importantly, compared with the original dG and FOLFOX4 regi-
mens, the simple administration schedules of these ‘MdG’ regimens
reduce patient and nurse time, and ensure that all patients may be
treated on an outpatient basis with only one visit to the hospital
every 2 weeks. In addition we found that these regimens helped foster
close relationships between patient, Community Nurse and Oncol-
ogy Unit, which in turn improved monitoring of toxicity during
treatment and palliative care after eventual disease progression.
The regimens are well tolerated. Grade 3 and 4 toxicity is
uncommon, even with OxMdG. Despite this, there were two unex-
pected deaths during OxMdG treatment (3.2%), underlining the
need for rigorous patient and staff education. One of the deaths
was due to overwhelming MRSA septicaemia, without neutropenia,
attributable to the venous access device; the other was due to
neutropenic sepsis managed too late and at a non-oncology hospi-
tal; both were potentially avoidable.
The efﬁcacy of OxMdG was particularly encouraging in the
cohort of unpretreated patients: 72% conﬁrmed PR/CR, scored
by an independently appointed external team. The 95% c.i. for this
response rate (50–88%) is consistent with the response rates for
similar regimens in two industry-run trials: FOLFOX4 gave
responses in 50% of 210 patients, 95% c.i. 42–58% (de Gramont
et al, 2000), and FOLFOX6 in 56% of 109, 95% c.i. 46–66%
(Tournigand et al, 2001).
Equally noteworthy is the long overall survival observed in
patients treated with MdG alone as ﬁrst-line therapy. Sixty-eight
percent of these patients received second-line and subsequent treat-
ments after MdG; this raises the issue of whether patients are better
served by ﬁrst-line combination therapy or, as in this group, by
maximising the period of disease control with an optimum FU/
LV regimen before introducing other drugs. This question is being
addressed in the current UK Medical Research Council phase III
trial ‘Fluorouracil, Oxaliplatin and CPT-11: Use and Sequencing’
(FOCUS), which uses the MdG, OxMdG and IrMdG regimens as
described here.
FOCUS is also an opportunity to evaluate the safety of OxMdG
in the multicentre setting. Rigorous centre accreditation criteria are
used, and adverse events are closely monitored. To date the record
is good: with over 150 patients treated with OxMdG so far, there
are no deﬁnite treatment-related deaths, and close vigilance
continues.
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